The Massachusetts Research Credit: A Technical Analysis of Schedule RC and the Section 38M Innovation Framework

Schedule RC is the primary tax schedule used by business corporations to calculate and claim the Massachusetts Research Credit against their corporate excise liability for qualified research expenses conducted within the Commonwealth. It functions as the administrative mechanism for documenting in-state innovation investments, allowing taxpayers to leverage a ten percent incremental credit based on methodologies that parallel Internal Revenue Code Section 41.

The Massachusetts Research Credit represents one of the most significant tax expenditures in the Commonwealth’s budget, serving as a pillar of the state’s “Innovation Economy.” This economy, which accounts for nearly forty percent of all jobs in Massachusetts, relies on the high concentration of research and development (R&D) activities in sectors such as life sciences, software, and advanced manufacturing.1 By providing a structured tax incentive through Massachusetts General Laws (M.G.L.) Chapter 63, Section 38M, the state effectively lowers the cost of innovation, encouraging firms to anchor their most complex and high-value technical operations within state borders. The following report provides an exhaustive examination of Schedule RC, its statutory origin, recent regulatory shifts—including the landmark expansion to financial institutions—and the technical nuances of its calculation methodologies.

Statutory Authority and the Legal Context of Section 38M

The legal foundation for the Massachusetts Research Credit is codified in M.G.L. ch. 63, § 38M. This statute establishes that any business corporation subject to the corporate excise under Chapter 63 is entitled to a credit against its tax liability for expenditures incurred for research activity conducted in Massachusetts.2 The statute’s design is intentionally incremental, meaning it does not reward total research spending but rather the increase in spending over a calculated historical base. This structure is intended to prevent the credit from becoming a windfall for static R&D budgets while providing a powerful incentive for expansion.

The Massachusetts legislature has historically adopted a “static” conformity to the federal research credit. Specifically, the terms “qualified research expenses,” “basic research payment,” and other definitions affecting the calculation are anchored to Section 41 of the Internal Revenue Code (IRC) as it was in effect on August 12, 1991.2 While this provides a degree of predictability, it also requires tax professionals to distinguish between modern federal tax updates and the historical definitions preserved under Massachusetts law. For instance, while federal law has moved through several iterations of the Alternative Simplified Credit (ASC), Massachusetts did not introduce its own version, the Alternative Simplified Method (ASM), until 2014, and did not fully phase in the ten percent rate until 2021.6

The credit is fundamentally non-refundable, meaning it can only be used to offset a taxpayer’s corporate excise liability for the year it is generated.7 However, any excess credit may be carried forward under two distinct rules. First, credits that exceed the current year’s liability can generally be carried forward for fifteen years.3 Second, credits that are limited by the statutory “75% rule”—which prevents the credit from offsetting more than 75% of the tax liability in excess of $25,000—may be carried forward indefinitely.10 This unique indefinite carryover provision ensures that high-innovation firms are not permanently penalized for having large research budgets relative to their current tax bills.

Eligibility Evolution: From Manufacturing to Financial Institutions

A central question in the administration of Schedule RC has always been the definition of an eligible “Business Corporation.” Historically, the Department of Revenue (DOR) maintained a restrictive view, interpreting the statute to apply only to manufacturing and traditional business corporations subject to tax under M.G.L. ch. 63, § 39.4 This left financial institutions, which are taxed under M.G.L. ch. 63, § 2, in a state of regulatory uncertainty.

The Landmark State Street Decision and TIR 25-3

The regulatory landscape was fundamentally altered by the 2024 decision of the Massachusetts Appellate Tax Board (Board) in State Street Corporation v. Commissioner of Revenue.13 The Board held that financial institutions are indeed entitled to claim the research credit under Section 38M, as the definition of “business corporation” in M.G.L. ch. 63, § 30(1) is sufficiently broad to encompass any entity subject to the Chapter 63 excise. The Board reasoned that the legislature did not intend to exclude entire sectors—such as banking and financial services—from the state’s primary innovation incentive, particularly as those sectors increasingly rely on proprietary technology and complex software development.

Following this decision, the DOR issued Technical Information Release (TIR) 25-3, which serves as the current governing guidance for financial institution eligibility.13 This TIR clarifies that banks and other financial institutions may now claim the research credit and, more importantly, may file amended returns or abatement applications to claim credits for prior years that are still within the statute of limitations.14 This represents a massive shift in state revenue policy, potentially unlocking millions of dollars in credits for the Commonwealth’s robust financial services cluster.

Treatment of S-Corporations and Partnerships

The application of the research credit to flow-through entities remains a point of distinction between federal and Massachusetts law. An S-corporation is eligible for the research credit against its own excise due under M.G.L. ch. 63, but the credit does not flow through to its individual shareholders.4 This means the credit can only be used to offset the S-corp’s entity-level taxes, such as the non-income measure of the excise or taxes on built-in gains. For partnerships and LLCs treated as partnerships, the credit is attributed to the owners based on their ownership interest, and those owners must then apply the credit against their own corporate or personal excise.8

Identifying Massachusetts Qualified Research Expenses (QREs)

The technical core of Schedule RC is the identification of Massachusetts Qualified Research Expenses (QREs). To qualify, an expenditure must meet a two-pronged test: it must be a qualified research expense under IRC § 41(b), and the research activity must have been conducted within the borders of Massachusetts.3

The Four-Part Test for Activity Qualification

The Commonwealth adheres to the federal four-part test to determine if an activity qualifies as “research” for tax purposes.9 The activity must be technological in nature, intended for a permitted purpose (such as improving the function or reliability of a product), and must involve a process of experimentation designed to eliminate uncertainty regarding the design or method of achieving a result.

Geographic Nexus and Expense Categories

The geographic requirement is strictly interpreted by the DOR. Only the portion of expenses attributable to activity in Massachusetts is includable on Schedule RC. If research services are performed both inside and outside the state, the expenses must be prorated.20 The expenses are categorized into four primary buckets on Schedule RC:

Clinical trials represent a significant portion of QREs for the state’s life sciences firms. Guidance provided in 830 CMR 63.38M.1 clarifies that while the management and direction of clinical trials performed by employees in Massachusetts are eligible, the actual costs of conducting trials at out-of-state medical facilities are generally excluded.21 This creates an administrative burden for firms to track the exact location of their clinical testing activities.

Calculation Methodologies: Traditional vs. Alternative Simplified Method

Schedule RC provides taxpayers with two options for determining the credit amount for taxable years beginning on or after January 1, 2015. This choice is often the most critical decision in a taxpayer’s R&D tax strategy.

Option 1: The Traditional Method (Section 38M(a))

The traditional method is based on the pre-2015 calculation logic. The credit equals 10% of the excess of the current year’s QREs over a “base amount,” plus 15% of basic research payments.2 The base amount is calculated as the product of the taxpayer’s average annual gross receipts for the four preceding years and a fixed-base ratio.4

Under modern rules, the fixed-base ratio is a “rolling” figure, determined by dividing total QREs for the third and fourth preceding years by the total gross receipts for those years.4 This ratio is capped at 16%.4 Furthermore, the base amount cannot be less than 50% of the current year’s QREs.4 This “50% floor” limits the credit to an incremental amount, ensuring the incentive is focused on growth rather than baseline activity.

Option 2: The Alternative Simplified Method (ASM) (Section 38M(b))

The ASM was introduced to simplify compliance and allow firms with fluctuating R&D budgets to still benefit from the credit.3 Under the ASM, the credit is 10% (for years beginning in 2021) of the amount by which current QREs exceed 50% of the average QREs from the three preceding years.7

If a corporation did not have QREs in each of the three preceding years, the ASM credit is simply calculated as 5% of the current year’s QREs.4 This provides a “startup” rate for new innovators who have not yet established a three-year history of research spending.

Election to Use Massachusetts Gross Receipts

Regardless of the method chosen, a corporation may elect to calculate its gross receipts—and its fixed-base ratio—using only Massachusetts-sourced receipts instead of federal gross receipts.10 This election is generally binding for three taxable years.15 For multi-state corporations with significant nationwide sales but concentrated research efforts in Massachusetts, this election can drastically lower the “base amount” threshold, thereby increasing the resulting credit.

Defense-Related Activities and the 2024 Mass Leads Act

Massachusetts law allows corporations to separate their research activities into “defense-related” and “non-defense” categories.10 If this election is made, the corporation must file two separate Schedule RCs—one for defense and one for everything else—and combine the results on the Credit Manager Schedule.4

Historically, defense activities were limited to contracts involving NASA or military arms.10 However, the 2024 “Mass Leads Act” (St. 2024, c. 238) expanded this definition significantly.24 Effective November 20, 2024, defense-related activities now include research related to biosecurity, vaccines, antibodies, and medicines used to treat threats from chemical, biological, or radiological sources.4 This change recognizes the strategic importance of the state’s pharmaceutical sector in national security and biodefense, allowing these firms to potentially benefit from separate, more favorable base-amount calculations for their defense-oriented work.

Aggregated Groups and Combined Reporting Dynamics

Massachusetts requires that corporations under common control calculate the research credit on an aggregated basis.22 This prevents a group from shifting expenses between entities to maximize the credit through artificial base-amount manipulation.

The Mechanism of Aggregation

The aggregation process follows a specific sequence under 830 CMR 63.38M.1(7) 10:

1. Combined Computation: The group is treated as a single taxpayer. All members’ QREs and basic research payments are added together, and all inter-company payments are eliminated.10
2. Shared Thresholds: The group shares a single $25,000 threshold for the 100% credit utilization rule.4
3. Proportional Allocation: Once the group credit is determined, it is allocated to each member corporation based on its share of the group’s total QREs.4
4. Flow-Through Integration: If a member of the group is a partner in a partnership, the partnership’s QREs and gross receipts are attributed to the corporate partner based on its ownership percentage, as demonstrated in the XYZ group example in the regulations.18

Limitations on Applying the Credit Against Excise

Calculating the credit on Schedule RC is only the first step; the second step is determining how much can actually be applied to the current year’s tax bill. Massachusetts law imposes several caps to ensure the state maintains a baseline of revenue.

The 75% Rule and the $456 Floor

The research credit cannot reduce a corporation’s excise below the statutory minimum tax of $456.3 Beyond the minimum tax, the amount of credit that can be used is limited by a dual-tier cap 3:

• First $25,000: The credit can offset 100% of the first $25,000 in corporate excise due.4
• Excess over $25,000: For any excise liability exceeding $25,000, the credit can offset only 75% of that liability.15

This means a corporation with a $1,000,000 tax bill can only use the research credit to offset up to $756,250 ($\$25,000 + 75\% \text{ of } \$975,000$). The remaining $243,750 must be paid in cash, though the credit that was “blocked” by the 75% rule can be carried forward indefinitely.3

Carryover and Expiration

The carryover rules for the Massachusetts research credit are among the most taxpayer-friendly in the country, provided the corporation remains in business and continues to file returns.

The Life Sciences Refundability Window

For certified life sciences companies, the non-refundable nature of the Section 38M credit can be partially circumvented through a specialized program administered by the Massachusetts Life Sciences Center (MLSC).28

Under the Life Sciences Tax Incentive Program, a certified company can apply for a refund of its excess research credits. If approved, the company can receive a cash refund equal to 90% of the unused credits generated during the year.9 To qualify for this refund, a company must commit to specific job creation and retention targets in the state, generally hiring at least 10 new permanent full-time employees (or 5 in Gateway Municipalities).28 This program is competitive and subject to an annual cap, which the 2024 Mass Leads Act increased from $30 million to $40 million to further support the biotech cluster.24

Administrative Guidance and Technical Information Releases

The administration of Schedule RC is heavily influenced by Technical Information Releases (TIRs) and Department of Revenue regulations. These documents provide the “how-to” for complex filing situations.

TIR 14-13 and TIR 14-16: The Calculation Bedrock

These two TIRs provided the initial guidance for the 2014 legislative reforms. TIR 14-13 focused on the methodology for calculating the base amount and the new fixed-base ratio, while TIR 14-16 provided the phase-in schedule for the ASM and modernized tax administration by allowing for electronic notifications.3

830 CMR 63.38M.1 vs. 63.38M.2

The original regulation, 63.38M.1, remains the authoritative source for definitions of research activity and the “geographic nexus” rules for wages and supplies.18 The proposed regulation, 63.38M.2, was introduced to address the post-2015 world of the ASM and rolling fixed-base ratios.5 While portions of the second regulation remain in proposed form, the DOR generally expects taxpayers to follow the logic laid out in the 2024 and 2025 Schedule RC instructions, which incorporate the core tenets of these proposed rules.4

Audit Guidelines and Documentation Requirements

The DOR requires taxpayers to maintain meticulous records to support the claims made on Schedule RC. In the event of an audit, a corporation must be able to produce 10:

• Project Lists: Detailed narratives of the research projects and how they meet the four-part test.
• Wage Substantiation: Time-tracking data or contemporaneous interview notes linking employee time to specific Massachusetts research projects.21
• Contract Proof: Evidence of where third-party contractors actually performed their research (e.g., facility addresses in Massachusetts).21

Comprehensive Credit Calculation Example

To demonstrate the practical application of Schedule RC and its associated limitations, consider the case of AlphaRobotics Inc., a mid-sized advanced manufacturing firm located in Worcester, Massachusetts.

Scenario Data (Tax Year 2024)

• 2024 MA QREs: $5,000,000
• Avg. Gross Receipts (Prior 4 Years): $40,000,000
• Historical Fixed-Base Ratio (based on yrs 3 and 4 lookback): 8%
• Prior 3-Year QREs (2021-2023): $4,000,000, $4,200,000, and $4,400,000
• 2024 Corporate Excise Liability: $600,000

Calculation Part 1: Traditional Method (Option 1)

1. Fixed-Base Ratio: 8% (Given).4
2. Base Amount: $Avg. Receipts \times Ratio = \$40,000,000 \times 0.08 = \$3,200,000$.15
3. Check 50% Floor: $50\% \text{ of } \$5,000,000 = \$2,500,000$. Since $3.2M > $2.5M, the base amount remains $3,200,000.4
4. Excess QREs: $\$5,000,000 – \$3,200,000 = \$1,800,000$.
5. Tentative Credit: $\$1,800,000 \times 10\% = \$180,000$.

Calculation Part 2: Alternative Simplified Method (Option 2)

1. 3-Year Avg. QREs: $(\$4M + \$4.2M + \$4.4M) / 3 = \$4,200,000$.
2. ASM Base (50% of Avg.): $\$4,200,000 \times 0.50 = \$2,100,000$.6
3. Excess QREs: $\$5,000,000 – \$2,100,000 = \$2,900,000$.
4. Tentative Credit: $\$2,900,000 \times 10\% = \$290,000$.

Conclusion: AlphaRobotics would elect the ASM method on Schedule RC to maximize its credit at $290,000.

Calculation Part 3: Application Against Excise

AlphaRobotics has a total excise of $600,000.

1. Step 1 ($25k offset): Offset 100% of the first $\$25,000$. Remaining excise: $\$575,000$.
2. Step 2 (75% offset): Offset 75% of the remaining excise. $\$575,000 \times 0.75 = \$431,250$.3
3. Maximum Allowable Credit Use: $\$25,000 + \$431,250 = \$456,250$.
4. AlphaRobotics Actual Use: Since its tentative credit ($290,000) is less than the maximum allowable ($456,250), it can use the entire $\$290,000$ this year.
5. Final Tax Bill: $\$600,000 – \$290,000 = \$310,000$.

Federal Section 174 Conformity and Potential Complexity

One of the most pressing issues facing Massachusetts tax departments is the conflict between the state research credit and federal Section 174 capitalization rules.19

Since 2022, federal law has required companies to capitalize and amortize R&D expenses over five years (or fifteen years for foreign R&D).19 Massachusetts generally conforms to the current IRC for corporate net income calculations, meaning companies must also capitalize these costs for state excise purposes.35 This capitalization increases the current-year taxable income, which in turn increases the corporate excise liability. While this allows for more “room” to use the research credit under the 75% rule, it also creates a massive record-keeping challenge to track the different amortization schedules for state and federal purposes, especially in states that might choose to “decouple” from the federal rule.34

Statistical Overview of the Research Credit’s Economic Reach

The scale of the research credit is a testament to the Commonwealth’s commitment to high-tech investment. Data from the Massachusetts Innovation Economy Index and the DOR Tax Expenditure Budget highlight the following trends:

The concentration of these credits is highest in the “Service” sector—particularly computer system design and software—and the “Information” sector.39 In states with similar R&D profiles, such as Pennsylvania, the vast majority of recipients (over 97%) are small businesses, though nearly half of the total dollar value of the credits is claimed by the largest taxpayers.39 Massachusetts mirrors this trend, with a robust ecosystem of startups utilizing the 5% ASM rate and large pharmaceutical “anchors” utilizing the 10% traditional method to offset millions in excise liability.

Strategic Conclusions for Massachusetts Taxpayers

The Massachusetts Research Credit, claimed via Schedule RC, is not merely a tax calculation; it is a fundamental component of corporate strategy for firms operating in the Commonwealth. The recent legal and legislative developments—most notably the inclusion of financial institutions via TIR 25-3 and the 2024 expansion of defense-related activities—demonstrate a state government that is proactively refining its tax code to maintain a competitive edge.

For corporations, the strategic use of Schedule RC requires:

1. Methodological Flexibility: Continual analysis of whether the Traditional Method or the ASM yields the higher benefit as R&D spending patterns change.
2. Geographic Precision: Rigorous tracking of where R&D personnel are physically located to satisfy the DOR’s “in-state” requirement.
3. Aggregated Planning: Careful coordination within combined groups to ensure that the single $25,000 threshold and group-level gross receipts are optimized.
4. Life Sciences Certification: Engaging with the MLSC for those eligible to unlock the 90% refundability of excess credits, which remains one of the state’s most powerful liquidity tools for early-stage innovators.

As the global competition for technical talent and R&D investment intensifies, the Section 38M credit serves as an essential anchor, ensuring that the next generation of breakthroughs—whether in biotech, AI, or fintech—is designed, tested, and developed in Massachusetts. Schedule RC remains the vital link between these technological achievements and the financial incentives that make them possible.

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/